Status:
COMPLETED
Evaluation of the Effect of Levalbuterol on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborating Sponsors:
Sumitomo Pharma America, Inc.
Conditions:
Asthma
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The most commonly used drug for immediate relief of symptoms of asthma is the blue puffer, albuterol or salbutamol (Ventolin). Racemic albuterol is a mixture of two forms of albuterol which are mirror...
Detailed Description
The most commonly used drug for immediate relief of symptoms of asthma is the blue puffer, albuterol or salbutamol (Ventolin). Racemic albuterol is a mixture of two forms of albuterol which are mirror...
Eligibility Criteria
Inclusion
- Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55.
- Stable, mild atopic asthma with forced expiratory volume in one second (FEV1.0) greater than 70% of predicted for age and height, and not requiring any medical treatment other than short acting inhaled beta-agonists as needed.
- No recent or significant history of cigarette smoking (no cigarettes within six months prior to entry into the study; less than 10 pack-years cumulative history of cigarette smoking).
- Peak decrease in FEV1 in both early (0-2 hour) and late (3-7 hour) allergen-provoked response of \> 15% compared with the baseline (pre-allergen challenge) spirometric determination.
- Signed written informed consent to participate in the protocol; ability to return to the outpatient clinic for repeated clinic visits.
- No history of asthma exacerbations or acute intercurrent respiratory illness (viral respiratory syndrome, bronchitis, pneumonia) for a six week period preceding entry into the screening phase of the study.
Exclusion
- Significant gastrointestinal (including hepatic), hematological, cardiovascular, cerebrovascular or other body system disorder.
- History of an acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks.
- Baseline AST or ALT (indicators of liver damage) greater than twice the upper limit of the normal range for the local laboratory.
- History of allergy or hypersensitivity to short-acting beta-agonists.
- Inability to discontinue asthma medications for the duration of the study or receipt of oral or inhaled corticosteroids or leukotriene receptor antagonist in the three weeks prior to entry into the screening phase of the study.
- Recent (within the past 2 months) or planned (within the study period) lung volume reduction surgery.
- Psychosis, alcoholism, active substance abuse, or any personality disorder which would make compliance with this protocol problematic.
- Pregnant or nursing females.
- Any other medical or social condition which, in the opinion of the investigator, could confound the interpretation of the data derived from this study.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00320034
Start Date
April 1 2006
End Date
November 1 2009
Last Update
March 2 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.